‘Pipeline In A Product’ Nipocalimab Starts Delivering For J&J
Moving Into Phase III For HDFN
Johnson & Johnson splashed a lot of cash to get hold of the FcRn inhibitor and is exploring nearly a dozen indications. Nipocalimab has advanced in one of those this week, severe hemolytic disease of the fetus and newborn.
You may also be interested in...
J&J/Legend’s Carvykti Data Show Earlier-Line Efficacy As Commercial Headwinds Remain
The companies unblinded data from CARTITUDE-4, which met its primary endpoint, but analysts citing KOLs said they continue to face issues with limited manufacturing slots and out-of-spec product.
Cimzia Keeps Raking In The Cash As UCB Waits For New Products Impact
The Belgian group’s older products helped push 2022 revenues to the top of their guidance range as the peak sales forecast for the new epilepsy drug Fintepla is set at €800m.
Argenx CEO Shares Secrets Of Vyvgart’s Stellar Success
Leaving commercial hires to just a few months before drug approval is a mistake, Argenx CEO Tim Van Hauwermeiren told In Vivo sister publication Scrip, noting that the impressive launch achieved for Vyvgart for generalized myasthenia gravis in the US and Japan will be a steadier affair in Europe.